Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008 May;7(5):1001-6

Date

05/01/2008

Pubmed ID

18445656

DOI

10.1158/1535-7163.MCT-07-2422

Scopus ID

2-s2.0-49849083911 (requires institutional sign-in at Scopus site)   51 Citations

Abstract

Medullary thyroid carcinoma (MTC) is an uncommon malignancy of hereditary and sporadic presentation. Mutations in the RET proto-oncogene are involved in the pathogenesis of familial MTC and >50% of the sporadic cases. Currently, there is no effective treatment for recurrent or metastatic MTC. We report here a rapid response to a sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor)--based regimen in a patient with sporadic MTC who had advanced, progressive disease and a novel RET kinase aberration at exon 11 shown in tumor tissue.

Author List

Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R

Author

Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Amino Acid Sequence
Antineoplastic Agents
Benzenesulfonates
Carcinoma, Medullary
Cell Line, Tumor
Exons
Humans
Male
Molecular Sequence Data
Niacinamide
Phenylurea Compounds
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-ret
Pyridines
Quinolones
Thyroid Neoplasms